Guggenheim Maintains Buy on Pfizer, Raises Price Target to $33
Benzinga Newsdesk 16 hours ago
Analyst RatingsNewsPrice TargetHot
Guggenheim analyst Vamil Divan maintains Pfizer (NYSE:PFE) with a Buy and raises the price target from $31 to $33.
Guggenheim analyst Vamil Divan maintains Pfizer (NYSE:PFE) with a Buy and raises the price target from $31 to $33.